CBGA sits at the root of cannabinoid biosynthesis. Enzymatic action on CBGA produces the three principal cannabinoid acids found in the cannabis plant: THCA, CBDA, and CBCA. Any CBGA that escapes these enzymatic conversion pathways can decarboxylate under heat or ultraviolet light to yield CBG (cannabigerol) directly. Because downstream synthases compete for the same CBGA substrate, the relative concentrations of THCA, CBDA, and CBCA in any given cultivar reflect, in part, which synthase enzymes are most active.
Structurally, CBGA is a 22-carbon carboxylic acid with a resorcinyl core and a geranyl side chain. It is classed as a neutral precursor acid , analogous in role to CBCA, THCA, and CBDA , and, like those compounds, loses its carboxyl group (CO₂) upon decarboxylation to yield the corresponding neutral cannabinoid. In freshly harvested plant material, CBGA concentrations are typically low because efficient conversion by synthase enzymes limits its accumulation; cultivars selectively bred for high CBG content tend to be harvested early, before the synthases fully process the available CBGA.
Research into CBGA's own pharmacological interactions is at an early stage. In vitro studies have examined its behaviour at peroxisome proliferator-activated receptors (PPARs) and at enzymes in lipid metabolism pathways, but these findings are preliminary, have not been replicated at scale in human subjects, and do not establish any clinical indication. CBGA does not appear to bind with high affinity to cannabinoid receptors CB1 or CB2 under standard assay conditions, distinguishing its receptor profile from that of THC and CBD.
In Australia, CBGA extracted or isolated from cannabis is subject to the Therapeutic Goods (Poisons Standard) Instrument (the Poisons Standard). Cannabis-derived substances are scheduled depending on their THC content and intended use; researchers working with whole-plant extracts or isolated cannabinoid acids require appropriate licences under the Narcotic Drugs Act 1967 and must comply with TGA and state/territory permit conditions.
Sources:
- Taguchi C et al., "Biochemistry and molecular biology of cannabinoid biosynthesis in Cannabis sativa" , NCBI/PMC
- Medicinal Cannabis; Guidance Documents, TGA (Therapeutic Goods Administration)
- Navarro G et al., "Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor Complexes", NCBI/PMC